Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) is one of 41 publicly-traded companies in the “Industrial organic chemicals” industry, but how does it compare to its competitors? We will compare Cyclo Therapeutics to related businesses based on the strength of its profitability, institutional ownership, risk, earnings, analyst recommendations, valuation and dividends.
Risk & Volatility
Cyclo Therapeutics has a beta of -0.93, indicating that its stock price is 193% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics’ competitors have a beta of -129.53, indicating that their average stock price is 13,053% less volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Cyclo Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cyclo Therapeutics Competitors||272||1015||1294||40||2.42|
Cyclo Therapeutics currently has a consensus target price of $16.00, indicating a potential upside of 479.71%. As a group, “Industrial organic chemicals” companies have a potential upside of 20.38%. Given Cyclo Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Cyclo Therapeutics is more favorable than its competitors.
This table compares Cyclo Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cyclo Therapeutics Competitors||-435.63%||-59.61%||-0.06%|
Institutional & Insider Ownership
5.2% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Industrial organic chemicals” companies are owned by institutional investors. 12.3% of Cyclo Therapeutics shares are owned by insiders. Comparatively, 11.6% of shares of all “Industrial organic chemicals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Cyclo Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cyclo Therapeutics||$1.59 million||-$14.29 million||-1.22|
|Cyclo Therapeutics Competitors||$4.57 billion||$425.65 million||6.65|
Cyclo Therapeutics’ competitors have higher revenue and earnings than Cyclo Therapeutics. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Cyclo Therapeutics competitors beat Cyclo Therapeutics on 7 of the 12 factors compared.
About Cyclo Therapeutics (Get Rating)
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.